Digital phenotyping approaches and mobile devices enhance CNS biopharmaceutical research and development.
作者信息
Smith Daniel G
机构信息
Department of Clinical Research, Alkermes Incorporated, Waltham, MA, 02451, USA.
出版信息
Neuropsychopharmacology. 2018 Dec;43(13):2504-2505. doi: 10.1038/s41386-018-0222-6. Epub 2018 Sep 18.
Abstract
摘要
相似文献
1
Digital phenotyping approaches and mobile devices enhance CNS biopharmaceutical research and development.
Neuropsychopharmacology. 2018 Dec;43(13):2504-2505. doi: 10.1038/s41386-018-0222-6. Epub 2018 Sep 18.
2
The top prescription drugs of 2012 globally: biologics dominate, but small molecule CNS drugs hold on to top spots.
ACS Chem Neurosci. 2013 Jun 19;4(6):905-7. doi: 10.1021/cn400107y.
3
Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to Reality.
Clin Pharmacol Ther. 2018 Dec;104(6):1125-1135. doi: 10.1002/cpt.1100. Epub 2018 Jun 19.
4
Why is the global CNS pharmaceutical market so under-penetrated?
Drug Discov Today. 2002 Jan 1;7(1):5-7. doi: 10.1016/s1359-6446(01)02082-7.
5
An audience with...Luca Santarelli. Interview by Alexandra Flemming.
Nat Rev Drug Discov. 2013 Jan;12(1):14-5. doi: 10.1038/nrd3925.
6
Implications of sex-related differences in central nervous system disorders for drug research and development.
Nat Rev Drug Discov. 2021 Dec;20(12):881-882. doi: 10.1038/d41573-021-00115-6.
7
Digital devices and continuous telemetry: opportunities for aligning psychiatry and neuroscience.
Neuropsychopharmacology. 2018 Dec;43(13):2499-2503. doi: 10.1038/s41386-018-0172-z. Epub 2018 Aug 2.
8
Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
ACS Chem Neurosci. 2017 Mar 15;8(3):429-431. doi: 10.1021/acschemneuro.7b00040. Epub 2017 Feb 14.
9
Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
Drug Discov Today. 2012 Nov;17(21-22):1208-16. doi: 10.1016/j.drudis.2012.06.015. Epub 2012 Jun 30.
10
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products.
Pharm Res. 2021 May;38(5):739-757. doi: 10.1007/s11095-021-03037-5. Epub 2021 Apr 26.
引用本文的文献
1
Dualistic Dynamics in Neuropsychiatry: From Monoaminergic Modulators to Multiscale Biomarker Maps.
Biomedicines. 2025 Jun 13;13(6):1456. doi: 10.3390/biomedicines13061456.
2
Returning Individual Research Results from Digital Phenotyping in Psychiatry.
Am J Bioeth. 2024 Feb;24(2):69-90. doi: 10.1080/15265161.2023.2180109. Epub 2023 May 8.
3
Measuring functional outcomes in schizophrenia in an increasingly digital world.
Schizophr Res Cogn. 2022 Apr 7;29:100248. doi: 10.1016/j.scog.2022.100248. eCollection 2022 Sep.
4
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
J Parkinsons Dis. 2021;11(s1):S103-S109. doi: 10.3233/JPD-202428.
5
Digital Phenotyping in Bipolar Disorder: Which Integration with Clinical Endophenotypes and Biomarkers?
Int J Mol Sci. 2020 Oct 16;21(20):7684. doi: 10.3390/ijms21207684.
6
The Differential Impact of Social Media Use on Middle and High School Students: A Retrospective Study.
J Child Adolesc Psychopharmacol. 2019 Dec;29(10):746-752. doi: 10.1089/cap.2019.0071. Epub 2019 Jun 24.
本文引用的文献
1
Characterizing the clinical relevance of digital phenotyping data quality with applications to a cohort with schizophrenia.
NPJ Digit Med. 2018 Apr 6;1:15. doi: 10.1038/s41746-018-0022-8. eCollection 2018.
2
Digital biomarkers of cognitive function.
NPJ Digit Med. 2018 Mar 28;1:10. doi: 10.1038/s41746-018-0018-4. eCollection 2018.
3
Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials.
Alzheimers Dement (N Y). 2018 May 24;4:234-242. doi: 10.1016/j.trci.2018.04.003. eCollection 2018.
4
Relapse prediction in schizophrenia through digital phenotyping: a pilot study.
Neuropsychopharmacology. 2018 Jul;43(8):1660-1666. doi: 10.1038/s41386-018-0030-z. Epub 2018 Feb 22.
5
A comparison of passive and active estimates of sleep in a cohort with schizophrenia.
NPJ Schizophr. 2017 Oct 16;3(1):37. doi: 10.1038/s41537-017-0038-0.
6
The digital mental health revolution: Opportunities and risks.
Psychiatr Rehabil J. 2017 Sep;40(3):263-265. doi: 10.1037/prj0000285.
7
New dimensions and new tools to realize the potential of RDoC: digital phenotyping via smartphones and connected devices.
Transl Psychiatry. 2017 Mar 7;7(3):e1053. doi: 10.1038/tp.2017.25.
8
Detection of Motor Impairment in Parkinson's Disease Via Mobile Touchscreen Typing.
IEEE Trans Biomed Eng. 2017 Sep;64(9):1994-2002. doi: 10.1109/TBME.2017.2664802. Epub 2017 Feb 20.
9
Resting-state connectivity biomarkers define neurophysiological subtypes of depression.
Nat Med. 2017 Jan;23(1):28-38. doi: 10.1038/nm.4246. Epub 2016 Dec 5.
10
Precision psychiatry: a neural circuit taxonomy for depression and anxiety.
Lancet Psychiatry. 2016 May;3(5):472-80. doi: 10.1016/S2215-0366(15)00579-9. Epub 2016 Apr 14.
Zotero 插件